2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3734 Cell state dynamics reveal immune dysregulation in pediatric chronic myeloid leukemia

Tiffany K. Ybarra, PhD, David E. Frankhouser, PhD2, Ya-Huei Kuo, PhD3, Guido Marcucci, MD4, Nobuko Hijiya, MD5, Russell C. Rockne, PhD6, Kathleen Sakamoto, MD,PhD7
1 Stanford University, School of Medicine, Stanford, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 Columbia University, Irving Medical Center, New York, New York, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 Stanford University, School of Medicine, Stanford, California, United States

Pediatric chronic myeloid leukemia (CML) is a rare hematologic malignancy with clinical characteristics distinct from adult CML, including higher leukocyte counts and more pronounced splenomegaly at diagnosis. Although tyrosine kinase inhibitors have drastically improved outcomes, the molecular mechanisms underlying pediatric CML remain poorly understood, limiting the development of age-specific therapeutic strategies and our understanding of treatment response and disease progression. To define age-dependent molecular and immune features of pediatric CML, we integrated transcriptomic, single-cell, functional and immunophenotypic analyses.

Bulk RNA sequencing was performed on bone marrow-derived CD34+ hematopoietic stem and progenitor cells (HSPCs) from pediatric patients (n=10, 9-13 years) and adult patients (n=10, 33-62 years) with chronic-phase CML and age-matched healthy controls. Comparative transcriptomic analysis identified transcriptional programs unique to pediatric CML, including differential regulation of Rho GTPase signaling, B cell development pathways, and cellular metabolic processes compared with adult CML, highlighting potential age-specific mechanisms of leukemogenesis.

Single-cell RNA sequencing further demonstrated significant remodeling of the hematopoietic compartment in pediatric CML, characterized by depletion of CD34+ pro-B cells and reduced expression of HLA class II genes within leukemic CD34+ populations, suggesting impaired immune recognition. Given the established association between HLA-DR loss and immune evasion, we investigated its functional significance using activated healthy donor T cell co-culture assays. HLA-DR+ CML cell lines (MOLM-1 and MOLM-6) exhibited significantly greater T cell-mediated apoptosis than the HLA-DR- cell line K562, supporting a functional role for HLA-DR downregulation in promoting immune escape and leukemic cell survival. Immunophenotyping analysis of primary pediatric CML bone marrow further demonstrated altered HSPC composition, including differential HLA-DR expression across CD34+CD38+ and CD34+CD38- stem and progenitor populations and a shift toward common myeloid progenitor (CMP) and megakaryocyte-erythroid progenitor (MEP) compartments, consistent with lineage bias in pediatric disease.

These findings establish pediatric CML as a biologically distinct leukemia characterized by altered immune regulation, depletion of early B cell progenitors, and dysregulated HLA class II expression within leukemic stem and progenitor cells. These age-dependent molecular features provide a potential mechanistic basis contributing to pediatric CML pathogenesis and identify HLA class II-associated pathways as candidate biomarkers and age-specific therapeutic targets.

Tiffany K. Ybarra, PhD: No relevant conflicts of interest to declare.